



From the Office of the President

March 29, 2007

To our Loyal Customers,

It has recently been brought to our attention; one or more of our esteemed competitors has enhanced their sales and marketing programs by notifying current and potential RyMed customers of FDA Regulatory activities with our Company. Many of those who have contacted us about the competitive activity find it unusual that a few of our competitors are attempting to sell their products, not through attributes of their own products, but by attempting to damage the well established reputation of RyMed.

RyMed would like to set the record straight with the facts. Following is a summary of all of the recent FDA activity:

Voluntary Recall:

In May, 2006 RyMed initiated a voluntary recall of specific lots of the *InVision-Plus® Neutral® I.V. Connector*. These lots exhibited an extremely small defect rate (believed to be less than 0.4%) for weld failures which may allow the Connector to separate during use. The recall was initiated by RyMed because it was believed to be in the best interest of our customers and their patients.

The Notice of this recall was posted on the FDA website on January 10, 2007. This initial posting listed the recall as a Class III, status: ongoing.

A subsequent posting was made on the FDA website on January 24, 2007. This posting reclassified the recall as a Class II, status: completed.

In March, 2007 the FDA issued a notice to RyMed that the Agency considers the recall completed and terminated.

FDA Inspection:

The FDA conducted an inspection of RyMed in November, 2006. A standard form 483 was issued listing specific items which the FDA believed should be addressed by RyMed Technologies, Inc.

Corrective Actions were immediately implemented by the Company and a response stating the actions taken by RyMed was provided to the FDA. The corrective actions and response back to the FDA were taken by RyMed in less time than agreed upon with the Agency.

Warning Letter:

In February, 2007 the FDA issued a Warning Letter to RyMed.

An outside party reading the Letter would most likely draw the conclusion that RyMed has not taken corrective action to the Form 483 items, nor notified the FDA of the actions taken by the Company. This is COMPLETELY INACCURATE. RyMed does now and always has taken compliance with Regulatory agencies extremely serious.

In March, 2007 RyMed's Quality Assurance Manager and Vice President of Operations met with the senior Compliance officials at the Dallas District FDA office to review the Form 483 Corrective Actions as submitted to the FDA. This meeting was requested by RyMed.

It was expressed by the FDA the corrective actions provided to the Agency were adequate and no further actions were requested by the FDA.

The Company regrets the above matter occurred, but please be assured RyMed will always take quality of its products, the needs of our customers and their patients extremely serious. Please contact your RyMed Territory Manager or the RyMed Quality Assurance Department should you have any further questions regarding this matter.

Sincerely,

Dana Wm. Ryan
President & CEO

Anna McCutchen

Quality Assurance Manager
RyMed Technologies, Inc.
512-301-7334